meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
chemotherapy
platinum-based chemotherapy
platinum derivate
platinum association
platin and fluoropyrimidine
FOLFOX (5FU/leucovorin/oxaliplatin)
gene alteration target therapy
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
encorafenib plus binimetinib
HER inhibitor
HER2 inhibitor
tucatinib based treatment
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
atezolizumab plus cometinib
atezolizumab plus FOLFOXIRI plus bevacizumab
atezolizumab plus SoC
avelumab based treatment
avelumab alone
dostarlimab based treatment
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
no study with result for this clinical condition